A clinical trial (NCT01961765) revealed favorable tolerability of cabozantinib in AML patients, with notable potency observed as an inhibitor of FLT3/ITD-altered tyrosine kinases [142]. This evidence concerns the gene FLT3 and acute myeloid leukemia.